BBBert Van Den Bogerd

Bert Van Den Bogerd

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bert Van Den Bogerd has a total of 67 co-authors. Here are the top co-authors by number of shared publications:

  • Sorcha Ní Dhubhghaill

    Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB), 1090 Brussels, Belgium

    10 shared publications
  • Carina Koppen

    Visual Optics Lab Antwerp (VOLANTIS), Faculty of Medicine and Health Sciences, Antwerp University, Wilrijk, Belgium; Dept. of Ophthalmology, Antwerp University Hospital, Edegem, Belgium

    9 shared publications
  • Carina Koppen

    5 shared publications
  • Nadia Zakaria

    Faculty of Medicine and Health Sciences, Department of Ophthalmology, Visual Optics and Visual Rehabilitation, University of Antwerp, Campus Drie Eiken, T building, T4-Ophthalmology, Universiteitsplein 1, 2610 Antwerp, Belgium

    4 shared publications
  • Sorcha Ní Dhubhghaill

    Department of Ophthalmology, Brussels University Hospital, Jette, Belgium

    4 shared publications
  • Hendrik Vercammen

    Antwerp Research Group for Ocular Science (ARGOS), Translational Neurosciences, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium; Department of Ophthalmology, Antwerp University Hospital, Edegem, Belgium; DrugVision Lab, University of Antwerp, Wilrijk, Belgium

    3 shared publications

Latest Publications

  • Open Access

    Forecasting a clear vision: How QSAR modeling catalyzes small molecule discovery in the field of corneal endothelial regeneration

    by Charissa Witters, Hans De Winter, Maxim Le Compte, Martin Ondra, Debbie Le Blon, Bert Van Den Bogerd, Christophe Deben, Marián Hajdúch, Carina Koppen, Hendrik Vercammen

  • Open Access

    Clinical Applications of Corneal Cells Derived from Induced Pluripotent Stem Cells

    by Yixin Luan, Aytan Musayeva, Jina Kim, Debbie Le Blon, Bert van Den Bogerd, Mor M. Dickman, Vanessa L. S. LaPointe, Sorcha Ni Dhubhghaill, Silke Oellerich

    Corneal diseases are among the leading causes of blindness worldwide and the standard treatment is the transplantation of corneal donor tissue. Treatment for cornea-related visual impairment and blindness is, however, often constrained by the global shortage of suitable donor grafts. To alleviate the shortage of corneal donor tissue, new treatment options have been explored in the last decade. The discovery of induced pluripotent stem cells (iPSCs), which has revolutionized regenerative medicine, offers immense potential for corneal repair and regeneration. Using iPSCs can provide a renewable source for generating various corneal cell types, including corneal epithelial cells, stromal keratocytes, and corneal endothelial cells. To document the recent progress towards the clinical application of iPSC-derived corneal cells, this review summarizes the latest advancements in iPSC-derived corneal cell therapies, ranging from differentiation protocols and preclinical studies to the first clinical trials, and discusses the challenges for successful translation to the clinic.


  • Open Access

    “Keep on ROCKIn”: Repurposed ROCK inhibitors to boost corneal endothelial regeneration

    by Hendrik Vercammen, Martin Ondra, Jana Kotulova, Edgar Cardenas De La Hoz, Charissa Witters, Katerina Jecmenova, Maxim Le Compte, Christophe Deben, Sorcha Ní Dhubhghaill, Carina Koppen, et al.


  • Open Access

    Belgian Endothelial Surgical Transplant of the Cornea (BEST cornea) protocol: clinical and patient-reported outcomes of Ultra-Thin Descemet Stripping Automated Endothelial Keratoplasty (UT-DSAEK) versus Descemet Membrane Endothelial Keratoplasty (DMEK) – a multicentric, randomised, parallel group pragmatic trial in corneal endothelial decompensation

    by Sorcha Ní Dhubhghaill, Barbara de Bruyn, Ilse Claerhout, Kim Claes, Ann Deconinck, Heleen Delbeke, Manon Huizing, Iva Krolo, Marc Muijzer, Silke Oellerich, et al.

    Objectives Corneal blindness is the third most frequent cause of blindness globally. Damage to the corneal endothelium is a leading indication for corneal transplantation, which is typically performed by lamellar endothelial keratoplasty. There are two conventional surgical techniques: Ultra-Thin Descemet Stripping Automated Endothelial Keratoplasty (UT-DSAEK) and Descemet Membrane Endothelial Keratoplasty (DMEK). The purpose of this study is to compare both techniques. Methods and analysis The trial compares UT-DSAEK and DMEK in terms of clinical and patient reported outcomes using a pragmatic, parallel, multicentric, randomised controlled trial with 1:1 allocation with a sample size of 220 participants across 11 surgical centres. The primary outcome is the change in best-corrected visual acuity at 12 months. Secondary outcomes include corrected and uncorrected vision, refraction, proportion of high vision, quality of life (EQ-5D-5L and VFQ25), endothelial cell counts and corneal thickness at 3, 6 and 12 months follow-up appointments. Adverse events will also be compared 12 months postoperatively. Ethics and dissemination The protocol was reviewed by ethical committees of 11 participating centres with the sponsor centre issuing the final definitive approval. The results will be disseminated at clinical conferences, by patient partner groups and open access in peer-reviewed journals. Governance of the trial Both, trial management group and trial steering committee, are installed with representatives of all stakeholders involved including surgeons, corneal bankers, patients and external experts. Trial registration number NCT05436665.


  • Open Access

    Corneal Neurotization—Indications, Surgical Techniques and Outcomes

    by Diana Carmen Dragnea, Iva Krolo, Carina Koppen, Callum Faris, Bert Van Den Bogerd, Sorcha Ní Dhubhghaill

    Corneal neurotization is a promising surgical approach for the treatment of moderate to severe neurotrophic keratopathy. This technique aims to restore corneal sensation by transferring healthy nerves, either directly or via a conduit, to the anesthetic cornea. This review provides a report on the current state of development, evidence, and experience in the field. We summarize the data available from clinical reports and case series, placing an emphasis on the diversity of the surgical techniques reported. While these data are encouraging, they also highlight the need for a consensus in reporting outcomes and highlight how the next step will involve validating putative outcome parameters when researching and reporting corneal neurotization surgery.


  • An Overview of Advanced In Vitro Corneal Models: Implications for Pharmacological Testing

    by Joris Van Meenen, Sorcha Ní Dhubhghaill, Bert Van Den Bogerd, Carina Koppen

    The cornea is an important barrier to consider when developing ophthalmic formulations, but proper modeling of this multilayered tissue remains a challenge. This is due to the varying properties associated with each layer in addition to the dynamics of the tear film. Hence, the most representative models to date rely on animals. Animal models, however, differ from humans in several aspects and are subject to ethical limitations. Consequently, in vitro approaches are being developed to address these issues. This review focuses on the barrier properties of the cornea and evaluates the most advanced three-dimensional cultures of human corneal equivalents in literature. Their application potential is subsequently assessed and discussed in the context of preclinical testing along with our perspective toward the future. Impact statement: Most ocular drugs are applied topically, with the transcorneal pathway as the main administration route. Animal corneas are currently the only advanced models available, contributing to the drug attrition rate. Anatomical and physiological interspecies differences might account for a poor translatability of preclinical results to clinical trials, urging researchers to devise better corneal equivalents. This review elaborates on the emerging generation of three-dimensional in vitro models, which comprises spheroids, organoids, and organs-on-chips, which can serve as a stepping stone for advancements in this field.


  • Open Access

    Corneal endothelial wound healing: understanding the regenerative capacity of the innermost layer of the cornea

    by Hendrik Vercammen, Alina Miron, Silke Oellerich, Gerrit R.J. Melles, Sorcha Ní Dhubhghaill, Carina Koppen, Bert Van Den Bogerd


  • Tissue engineered scaffolds for corneal endothelial regeneration: a material's perspective

    by Jasper Delaey, Lobke De Vos, Carina Koppen, Peter Dubruel, Sandra Van Vlierberghe, Bert Van Den Bogerd

    Currently, the treatment of corneal diseases caused by damage to the corneal endothelium requires a donor cornea. Because of their limited availability (1 donor cornea for 70 patients in need), researchers are investigating alternative approaches that are independent of donor tissue. One of them includes the development of a tissue engineered scaffold onto which corneal endothelial cells are seeded. In order to function as a suitable substrate, some of its essential properties including thickness, permeability, transparency and mechanical strength should meet certain demands. Additionally, the membrane should be biocompatible and allow the formation of a functional endothelium on the surface. Many materials have already been investigated in this regard including natural, semi-synthetic and synthetic polymers. In the current review, we present an overview of their characteristics and provide a critical view on the methods exploited for material characterization. Next, also the suitability of scaffolds to serve their purpose is discussed along with an overview of natural tissues (e.g. amniotic membrane and lens capsule) previously investigated for this application. Eventually, we propose a consistent approach to be exploited ideally for membrane characterization in future research. This will allow a scientifically sound comparison of materials and membranes investigated by different research groups, hence benefitting research towards the creation of a suitable/optimal tissue engineered endothelial graft.


  • Open Access

    Characterisation of Gel-Forming Mucins Produced In Vivo and In Ex Vivo Conjunctival Explant Cultures

    by Sara I. Van Acker, Bert Van Den Bogerd, Zoë P. Van Acker, Agnė Vailionytė, Michel Haagdorens, Carina Koppen, Sorcha Ní Dhubhghaill, Darlene A. Dartt, Isabel Pintelon

    One key element to the health of the ocular surface encompasses the presence of gel-forming mucins in the pre-ocular tear film. Conjunctival goblet cells are specialized epithelial cells that secrete mucins necessary for tear film stability and general homeostasis. Their dysfunction can be linked to a range of ocular surface inflammation disorders and chronic injuries. To obtain new perspectives and angles to tackle mucin deficiency, the need for an accurate evaluation of their presence and corresponding mucin secretion in ex vivo conjunctival cultures has become a requisite. In vitro, goblet cells show a significant decrease in the production and secretion of gel-forming mucins, accompanied by signs of dedifferentiation or transdifferentiation. Explant cultures on laminin-treated CLP-PEG hydrogels can, however, support the production of gel-forming mucins. Together, we challenge the current paradigm to evaluate the presence of cultured goblet cells solely based on their general mucin (MUC) content through imaging analyses, showing the need for additional techniques to assess the functionality of goblet cells. In addition, we broadened the gel-forming mucin profile of in vivo goblet cells with MUC5B and MUC6, while MUC2 and MUC6 is added to the profile of cultured goblet cells.


  • Open Access

    Proliferation Increasing Genetic Engineering in Human Corneal Endothelial Cells: A Literature Review

    by Wout Arras, Hendrik Vercammen, Sorcha Ní Dhubhghaill, Carina Koppen, Bert Van Den Bogerd

    The corneal endothelium is the inner layer of the cornea. Despite comprising only a monolayer of cells, dysfunction of this layer renders millions of people visually impaired worldwide. Currently, corneal endothelial transplantation is the only viable means of restoring vision for these patients. However, because the supply of corneal endothelial grafts does not meet the demand, many patients remain on waiting lists, or are not treated at all. Possible alternative treatment strategies include intracameral injection of human corneal endothelial cells (HCEnCs), biomedical engineering of endothelial grafts and increasing the HCEnC density on grafts that would otherwise have been unsuitable for transplantation. Unfortunately, the limited proliferative capacity of HCEnCs proves to be a major bottleneck to make these alternatives beneficial. To tackle this constraint, proliferation enhancing genetic engineering is being investigated. This review presents the diverse array of genes that have been targeted by different genetic engineering strategies to increase the proliferative capacity of HCEnCs and their relevance for clinical and research applications. Together these proliferation-related genes form the basis to obtain a stable and safe supply of HCEnCs that can tackle the corneal endothelial donor shortage.